Dynamic sumoylation of promoter-bound general transcription factors facilitates transcription by RNA polymerase II.


Journal

PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074

Informations de publication

Date de publication:
09 2021
Historique:
received: 12 04 2021
accepted: 15 09 2021
revised: 11 10 2021
pubmed: 30 9 2021
medline: 15 12 2021
entrez: 29 9 2021
Statut: epublish

Résumé

Transcription-related proteins are frequently identified as targets of sumoylation, including multiple subunits of the RNA polymerase II (RNAPII) general transcription factors (GTFs). However, it is not known how sumoylation affects GTFs or whether they are sumoylated when they assemble at promoters to facilitate RNAPII recruitment and transcription initiation. To explore how sumoylation can regulate transcription genome-wide, we performed SUMO ChIP-seq in yeast and found, in agreement with others, that most chromatin-associated sumoylated proteins are detected at genes encoding tRNAs and ribosomal proteins (RPGs). However, we also detected 147 robust SUMO peaks at promoters of non-ribosomal protein-coding genes (non-RPGs), indicating that sumoylation also regulates this gene class. Importantly, SUMO peaks at non-RPGs align specifically with binding sites of GTFs, but not other promoter-associated proteins, indicating that it is GTFs specifically that are sumoylated there. Predominantly, non-RPGs with SUMO peaks are among the most highly transcribed, have high levels of TFIIF, and show reduced RNAPII levels when cellular sumoylation is impaired, linking sumoylation with elevated transcription. However, detection of promoter-associated SUMO by ChIP might be limited to sites with high levels of substrate GTFs, and promoter-associated sumoylation at non-RPGs may actually be far more widespread than we detected. Among GTFs, we found that TFIIF is a major target of sumoylation, specifically at lysines 60/61 of its Tfg1 subunit, and elevating Tfg1 sumoylation resulted in decreased interaction of TFIIF with RNAPII. Interestingly, both reducing promoter-associated sumoylation, in a sumoylation-deficient Tfg1-K60/61R mutant strain, and elevating promoter-associated SUMO levels, by constitutively tethering SUMO to Tfg1, resulted in reduced RNAPII occupancy at non-RPGs. This implies that dynamic GTF sumoylation at non-RPG promoters, not simply the presence or absence of SUMO, is important for maintaining elevated transcription. Together, our findings reveal a novel mechanism of regulating the basal transcription machinery through sumoylation of promoter-bound GTFs.

Identifiants

pubmed: 34587155
doi: 10.1371/journal.pgen.1009828
pii: PGENETICS-D-21-00490
pmc: PMC8505008
doi:

Substances chimiques

Chromatin 0
Small Ubiquitin-Related Modifier Proteins 0
Transcription Factors, General 0
RNA Polymerase II EC 2.7.7.-
Lysine K3Z4F929H6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009828

Subventions

Organisme : CIHR
ID : MOP-142282
Pays : Canada
Organisme : CIHR
ID : FDN-167265
Pays : Canada

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Genome Biol. 2014 Jul 31;15(7):422
pubmed: 25315341
Elife. 2018 Sep 07;7:
pubmed: 30192228
Mol Cell Proteomics. 2015 Jan;14(1):162-76
pubmed: 25381059
Bioessays. 2015 Oct;37(10):1095-105
pubmed: 26354225
Mol Cell. 2004 Feb 27;13(4):611-7
pubmed: 14992729
Genes Dev. 2010 Jun 15;24(12):1242-52
pubmed: 20504900
Genetics. 2021 Mar 31;217(3):
pubmed: 33789343
Mol Cell Biol. 2004 Feb;24(4):1709-20
pubmed: 14749386
J Biol Chem. 2005 Feb 11;280(6):4102-10
pubmed: 15590687
Molecules. 2021 Feb 05;26(4):
pubmed: 33562565
Nucleic Acids Res. 2021 Feb 26;49(4):1951-1971
pubmed: 33524141
Genome Res. 2015 Jun;25(6):897-906
pubmed: 25800674
Microb Cell. 2017 Oct 02;4(10):331-341
pubmed: 29082231
Biophys Rev. 2019 Feb;11(1):79-82
pubmed: 30627870
Mol Cell Proteomics. 2005 Mar;4(3):246-54
pubmed: 15542864
Nucleic Acids Res. 2014 Feb;42(3):1575-92
pubmed: 24194604
EMBO J. 2019 Aug 15;38(16):e102003
pubmed: 31313851
Nat Struct Mol Biol. 2017 Mar;24(3):325-336
pubmed: 28112733
PLoS One. 2009;4(4):e5267
pubmed: 19384408
PLoS One. 2015 Jun 19;10(6):e0129965
pubmed: 26090800
Mol Cell. 2017 Oct 5;68(1):130-143.e5
pubmed: 28918903
Genes Dev. 2012 Feb 15;26(4):350-5
pubmed: 22345516
PLoS One. 2015 Dec 03;10(12):e0143810
pubmed: 26633173
Epigenetics. 2009 Oct 1;4(7):440-4
pubmed: 19829068
Nucleic Acids Res. 2015 Jul 1;43(W1):W39-49
pubmed: 25953851
Methods Enzymol. 2003;371:491-8
pubmed: 14712723
Annu Rev Biochem. 2013;82:357-85
pubmed: 23746258
J Biol Chem. 2005 Mar 18;280(11):9937-45
pubmed: 15637059
PLoS Genet. 2019 Feb 14;15(2):e1007991
pubmed: 30763307
J Biol Chem. 2019 Dec 6;294(49):18784-18795
pubmed: 31676685
Mol Endocrinol. 2014 Oct;28(10):1719-28
pubmed: 25127374
Yeast. 1999 Jul;15(10B):963-72
pubmed: 10407276
Genes Dev. 2017 Jun 15;31(12):1257-1271
pubmed: 28733371
Sci Rep. 2019 Nov 29;9(1):17914
pubmed: 31784551
Nature. 1995 Jan 5;373(6509):78-81
pubmed: 7800043
Nature. 2000 Nov 9;408(6809):225-9
pubmed: 11089979
Dev Cell. 2013 Jan 14;24(1):1-12
pubmed: 23328396
Genes Dev. 1994 Dec 1;8(23):2868-78
pubmed: 7995524
Curr Genet. 2019 Dec;65(6):1307-1312
pubmed: 31093693
Mol Cell. 2018 Aug 2;71(3):409-418
pubmed: 30075142
Oncogene. 2014 Feb 13;33(7):921-7
pubmed: 23396363
J Biol Chem. 2004 Oct 1;279(40):41346-51
pubmed: 15292183
Biochim Biophys Acta. 2009 Jun-Aug;1789(6-8):451-9
pubmed: 19616654
Nature. 2012 Jan 18;483(7389):295-301
pubmed: 22258509
Mol Cell. 2009 Jan 16;33(1):124-35
pubmed: 19150434
Nucleic Acids Res. 2012 Nov 1;40(20):10172-86
pubmed: 22941651
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1039-1044
pubmed: 28096404
Nat Rev Mol Cell Biol. 2016 Sep;17(9):581-95
pubmed: 27435506
Curr Opin Genet Dev. 2005 Oct;15(5):536-41
pubmed: 16095902
Transcription. 2017 Aug 8;8(4):220-231
pubmed: 28379052
Genome Res. 2013 Oct;23(10):1563-79
pubmed: 23893515
Nat Cell Biol. 2014 Dec;16(12):1227-37
pubmed: 25344756
Nucleic Acids Res. 2014 Jul;42(13):8310-9
pubmed: 24981513
Nat Commun. 2019 Feb 15;10(1):777
pubmed: 30770815
Cell. 2012 Nov 9;151(4):807-820
pubmed: 23122649
Science. 2001 Jun 8;292(5523):1863-76
pubmed: 11313498
J Biol Chem. 2004 Oct 29;279(44):45662-8
pubmed: 15326169
Mol Cell Proteomics. 2005 Jan;4(1):73-83
pubmed: 15596868
Nature. 2016 May 11;533(7603):353-8
pubmed: 27193681
Nucleic Acids Res. 2015 Oct 30;43(19):9214-31
pubmed: 26240385
EMBO J. 2010 Feb 17;29(4):717-26
pubmed: 20094031
Nature. 2011 Oct 19;480(7375):94-8
pubmed: 22012259
Genetics. 2016 Dec;204(4):1433-1445
pubmed: 27770033

Auteurs

Mohammad S Baig (MS)

Department of Biology, York University, Toronto, Ontario, Canada.

Yimo Dou (Y)

Department of Biology, York University, Toronto, Ontario, Canada.

Benjamin G Bergey (BG)

Department of Biology, York University, Toronto, Ontario, Canada.

Russell Bahar (R)

Department of Biology, York University, Toronto, Ontario, Canada.

Justin M Burgener (JM)

Department of Biology, York University, Toronto, Ontario, Canada.

Marjan Moallem (M)

Department of Biology, York University, Toronto, Ontario, Canada.

James B McNeil (JB)

Department of Biology, York University, Toronto, Ontario, Canada.

Akhi Akhter (A)

Department of Biology, York University, Toronto, Ontario, Canada.

Giovanni L Burke (GL)

Department of Biology, York University, Toronto, Ontario, Canada.

Veroni S Sri Theivakadadcham (VS)

Department of Biology, York University, Toronto, Ontario, Canada.

Patricia Richard (P)

Stellate Therapeutics, New York, New York, United States of America.

Damien D'Amours (D)

Ottawa Institute of Systems Biology, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Emanuel Rosonina (E)

Department of Biology, York University, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH